DXSP DXS International Plc

 
TIDMDXSP 
 

DXS INTERNATIONAL PLC

Notification of Director / PDMR Dealing

The Board of DXS International plc (the "Company"), the AQSE Growth Market quoted clinical decision support developer and supplier of clinical decision support systems confirms that the Placing Shares and the Stakeholder Shares referred to in the Announcement of 17th May have this morning been admitted to trading on the Aquis Stock Exchange.

As part of the Placing and Conversion of Debt DL Services Limited, (a company owned and controlled by the Chief Executive's wife), has been issued with 753,244 Ordinary Shares in the Company at the Placing Price of 4p per share.

Following the transaction specified above Mr Immelman's interests, including those of persons closely associated with him, is 6,523,829 Ordinary Shares representing 10.19% of the issued share capital of the Company.

 
     Details of the person discharging managerial responsibilities 
1     / person closely associated 
---  -------------------------------------------------------------------------- 
a)   Name                           DL Services Limited 
---  -----------------------------  ------------------------------------------- 
2    Reason for the notification 
---  -------------------------------------------------------------------------- 
                                    a company owned and controlled by the 
a)   Position/status                 Chief Executive's wife 
---  -----------------------------  ------------------------------------------- 
     Initial notification 
b)    /Amendment                    Initial 
---  -----------------------------  ------------------------------------------- 
     Details of the issuer, emission allowance market participant, 
3     auction platform, auctioneer or auction monitor 
---  -------------------------------------------------------------------------- 
a)   Name                           DXS INTERNATIONAL PLC 
---  -----------------------------  ------------------------------------------- 
b)   LEI                            2138001R1KEUWTXEVJ44 
---  -----------------------------  ------------------------------------------- 
     Details of the transaction(s): section to be repeated for 
      (i) each type of instrument; (ii) each type of transaction; 
      (iii) each date; and (iv) each place where transactions 
4     have been conducted 
---  -------------------------------------------------------------------------- 
     Description of the financial 
      instrument, type of 
a)    instrument                    Ordinary Shares of 0.33p each 
--- 
 
     Identification code            ISIN GB00B2Q6HZ92 
 
b)   Nature of the transaction      Subscription 
---  -----------------------------  ------------------------------------------- 
c)   Price(s) and volume(s) 
---                                  -------------------  ------------------- 
                                     Price(s)                  Volume(s) 
---                                  -------------------  ------------------- 
   4p                                                                 753,244 
   -----------------------------------------------------  ------------------- 
 
d)   Aggregated information 
--- 
 
 - Aggregated volume 
 
 - Price 
 
e)   Date of the transaction        24 May 2023 
---  -----------------------------  ------------------------------------------- 
f)   Place of the transaction       Off market 
---  -----------------------------  ------------------------------------------- 
 

The Directors of DXS International plc accept responsibility for this announcement

Enquiries:

 
David Immelman (Chief Executive)            01252 719800 
 DXS International plc             david@dxs-systems.com 
Wrecclesham House 
 Wrecclesham Road 
 Farnham 
 Surrey 
 GU10 4PS 
www.dxs-systems.co.uk 
 
 
Corporate Advisor 
David Papworth 
 City & Merchant    0207 101 7676 
 
 
Corporate Broker 
Hybridan LLP 
 Claire Louise Noyce   020 3764 2341 
 

Note to Editors:

DXS International presents up to date treatment guidelines and recommendations, from Clinical Commissioning Groups and other trusted NHS sources, to doctors, nurses and pharmacists in their workflow and during the patient consultation. This effective clinical decision support ultimately translates to improved healthcare outcomes delivered more cost effectively which should significantly contribute towards the NHS achieving its projected efficiency savings.

(END) Dow Jones Newswires

May 24, 2023 07:00 ET (11:00 GMT)

DXS (AQSE:DXSP)
Historical Stock Chart
From May 2024 to Jun 2024

DXS (AQSE:DXSP)
Historical Stock Chart
From Jun 2023 to Jun 2024